---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-071082"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-06-23T20:05:25+00:00"
generated_at: "2026-06-23T20:06:24.773252+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MHRA aligns with INmune Bio on regulatory path for Ebstrocel in RDEB; UK MAA planned in 2026

## Summary
- MHRA minutes from May 12 pre-MAA meeting confirm agreement across CMC, non-clinical, and clinical evidence packages.
- Agency recognizes MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit in pain and pruritus.
- MHRA provided endpoint recommendations for confirmatory Phase 3, moving away from wound closure as primary focus.
- INmune Bio plans UK MAA submission in 2026; EU and US filings expected in late 2026 or early 2027.
- Company states MHRA alignment de-risks regulatory path for CORDStrom platform and conditional authorization.

## SEC filing metadata
- accession: 0001213900-26-071082
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-06-23T20:05:25+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026071082/0001213900-26-071082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026071082/ea0295635-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-071082
- JSON: https://secwatch.observer/filing/0001213900-26-071082.json
- Plain text: https://secwatch.observer/filing/0001213900-26-071082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.